WO2007122411A1 - Derives de diazepan-1-yl-sulfonyle pour le traitement du syndrome metabolique - Google Patents

Derives de diazepan-1-yl-sulfonyle pour le traitement du syndrome metabolique Download PDF

Info

Publication number
WO2007122411A1
WO2007122411A1 PCT/GB2007/001507 GB2007001507W WO2007122411A1 WO 2007122411 A1 WO2007122411 A1 WO 2007122411A1 GB 2007001507 W GB2007001507 W GB 2007001507W WO 2007122411 A1 WO2007122411 A1 WO 2007122411A1
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonyl
diazepane
dichloropyridin
compound
phenyl
Prior art date
Application number
PCT/GB2007/001507
Other languages
English (en)
Inventor
Peter William Rodney Caulkett
William Mccoull
Martin Packer
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2007122411A1 publication Critical patent/WO2007122411A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Definitions

  • This invention relates to chemical compounds, or pharmaceutically acceptable salts thereof. These compounds possess human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (1 l ⁇ HSDl) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man.
  • the invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit ll ⁇ HSDlin a warm-blooded animal, such as man.
  • Glucocorticoids Cortisol in man, corticosterone in rodents
  • Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196).
  • 1 l ⁇ HSDl knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 1 l ⁇ HSDl in lowering of plasma glucose and hepatic glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apo-lipoprotein AI levels. (Morton NM et al. 2001 ; J. Biol. Chem.
  • This phenotype is due to an increased hepatic expression of enzymes of fat catabolism and PP ARa. Again this indicates the utility of 1 l ⁇ HSDl inhibition in treatment of the dyslipidaemia of the metabolic syndrome.
  • 1 l ⁇ HSDl transgenic mice When expressed under the control of an adipose specific promoter, 1 l ⁇ HSDl transgenic mice have high adipose levels of corticosterone, central obesity, insulin resistant diabetes, hyperlipidaemia and hyperphagia. Most importantly, the increased levels of 1 l ⁇ HSDl activity in the fat of these mice are similar to those seen in obese subjects. Hepatic 1 l ⁇ HSDl activity and plasma corticosterone levels were normal, however, hepatic portal vein levels of corticosterone were increased 3 fold and it is thought that this is the cause of the metabolic effects in liver.
  • Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance.
  • Pancreatic islets express ll ⁇ HSDl and carbenoxolone can inhibit the effects of 11-dehydocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844).
  • 11 ⁇ HSDl inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.
  • Skeletal development and bone function is also regulated by glucocorticoid action.
  • 11 ⁇ HSDl is present in human bone osteoclasts and osteoblasts and treatment of healthy volunteers with carbenoxolone showed a decrease in bone resorption markers with no change in bone formation markers (Cooper MS et al 2000; Bone 27, 375-381). Inhibition of 11 ⁇ HSDl activity in bone could be used as a protective mechanism in treatment of osteoporosis.
  • Glucocorticoids may also be involved in diseases of the eye such as glaucoma.
  • 11 ⁇ HSD 1 has been shown to affect intraocular pressure in man and inhibition of 11 ⁇ HSD 1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
  • the WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course: s >
  • the patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with two or more of the following:
  • Ring A is phenyl or naphthyl, optionally substituted by 1, 2 or 3 substituents independently selected from R 1 ;
  • R 1 is selected from hydroxy, halo, trifluoromethyl, C(OH)(CF 3 )-, Ci. 4 alkoxy, cyano, Ci. 4 alkylcarbonyl and Ring B is phenyl or pyridyl, optionally substituted in the 2-, T-, 3- or 3'- positions (relative to the point of attachment) (where available) by 1 or 2 substituents independently selected from R 2 , and/or substituted in the 4- position (relative to the point of attachment) (where available) with a substituent selected from R 3 ;
  • R 2 is selected from halo, cyano, trifluoromethyl, Ci -4 alkyl and Ci_ 4 alkoxy;
  • R 3 is selected from halo, cyano, Ci -3 alkylsulfonyl and -CONR 4 R 5 ;
  • R 4 and R 5 are independently selected from hydrogen and Ci -4 alkyl; or
  • R 4 and R 5 together with the nitrogen to which they are attached form an azetidinyl or pyrrolidinyl ring; provided that the compound of formula (1) is not:
  • alkyl includes both straight and branched chain alkyl groups
  • “Ci. 4 alkyl” includes propyl, isopropyl and t-buty ⁇ .
  • references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only.
  • references to other radicals therefore
  • Ci- 4 alkylcarbonyl would include prop-1-ylcarbonyl and but-3-ylcarbonyl.
  • halo refers to fiuoro, chloro, bromo and iodo.
  • Examples of "Ci -4 alkoxy” include methoxy, ethoxy and propoxy. Examples of include formamido, acetamido and propionylamino. Examples of “Ci-salkylsulphonyl” include mesyl and ethylsulphonyl. include propionyl and acetyl. Examples of “Ci -3 alkyl” include methyl, ethyl, propyl and isopropyl. include the examples of "C 1-3 alkyl” as well as butyl, isobutyl, sec- butyl and tert-butyl.
  • hydroxyCi_ 4 alkyl examples include hydroxymethyl, hydroxyethyl, l-hydroxyprop-2-yl and l-hydroxyprop-3-yl.
  • C ⁇ alkylcarbonyl examples include methylcarbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl and tert-butylcarbonyl.
  • the present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof.
  • Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyi)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyi)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • Some compounds of the formula (1) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 1 l ⁇ HSDl inhibitory activity.
  • the invention relates to any and all tautomeric forms of the compounds of the formula (1) that possess 1 l ⁇ HSDl inhibitoiy activity.
  • Ring A is phenyl, optionally substituted by 1, 2 or 3 substituents independently selected from R 1 ;
  • Ring A is naphthyl, optionally substituted by 1, 2 or 3 substituents independently selected from R 1 ;
  • Ring A is phenyl, substituted by 1 or 2 substituents independently selected from R 1
  • Ring A is naphthyl 5)
  • R 1 is selected from hydroxy, fluoro, chloro, trifluoromethyl, Ci -4 alkyl, hydroxy C 1-4 alkyl, MeC(OH)(CF 3 )-, methoxy, cyano, methylcarbonyl and methylcarbonylamino
  • R 1 is selected from hydroxy, fluoro, chloro, trifluoromethyl, Ci -4 alkyl, hydroxy C 1-4 alkyl, methoxy, cyano, methylcarbonyl and methylcarbonylamino
  • R 1 is MeC(OH)(CF 3 )- 8) Ring B is phenyl
  • Ring B is pyridyl
  • Ring B is 2-pyridyl or 4-pyridyl
  • Ring B is substituted in the 2- and/or T- positions (relative to the point of attachment) by one or two, as appropriate, substituents independently selected from R 2 , particularly wherein R 2 is selected from chloro, fluoro and trifluoromethyl
  • Ring B is substituted on the 4- position (relative to the point of attachment) (where available) with a substituent selected from R 3
  • R 2 is selected from fluoro, chloro, cyano, trifluoromethyl, Ci_ 4 alkyl and C 1-4 alkoxy
  • R 2 is selected from fluoro, chloro, cyano, trifluoromethyl, Ci -4 alkyl and methoxy 15) R 2 is selected from chloro, fluoro and trifluoromethyl
  • R 3 is selected from fluoro, chloro, cyano, Ci -3 alkylsulfonyl, -CONHMe and -CONMe 2 17) R 3 is -CONR 4 R 5 wherein R 4 and R 5 together with the nitrogen to which they are attached form an azetidinyl or pyrrolidinyl ring.
  • suitable compounds of the invention are any one or more of the Examples or a salt thereof.
  • suitable compounds of the invention are any one or more of the following or a salt thereof: l-(3,5-dichloropyridin-4-yl)-4-(4-fluorophenyl)sulfonyl-l,4-diazepane; l-(2,4-dichlorophenyl)sulfonyl-4-(3,5-dichloropyridin-4-yl)-l,4-diazepane; l-(3,5-dichloropyridin-4-yl)-4-(3-methylphenyl)sulfonyl-l,4-diazepane; 1 -(3 ,5 -dichloropyridin-4-yl)-4-(4-methylphenyl)sulfonyl- 1 ,4-diazepane;
  • Another aspect of the present invention provides a process for preparing a compound of formula (1) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises any one of processes a) to c): a) reaction of a compound of Formula (2) with a compound of Formula (3):
  • Examples of conversions of a compound of Formula (1) into another compound of Formula (1) include functional group interconversions such as hydrolysis, hydrogenation, hydrogenolysis, oxidation or reduction, and/or further functionalisation by standard reactions such as amide or metal-catalysed coupling, or nucleophilic displacement reactions.
  • Suitable conditions for the above processes a) to c) are as follows.
  • a) Process a) may be carried out in a suitable solvent such as DCM, DMF, pyridine or water, typically with the addition of a base such as triethylamine, DIPEA, pyridine, or aqueous sodium hydroxide.
  • Process b) may be carried out without solvent, or in a suitable solvent such as DMA, DMF or xylene; typically the reaction is carried out without solvent at elevated temperature, using Microwave or conventional heating.
  • Compounds of formula (4) may be made by reaction of a compound of Formula (10) with a compound of Formula (11):
  • X 4 is a leaving group and R is hydrogen or a suitable protecting group, followed by removal of said protecting group if appropriate;
  • Process c) is typically carried out in an anhydrous aprotic solvent such as THF or diethyl ether;
  • suitable organometallic reagents for process c) are alkyl or aryl magnesium halides (Grignard reagent), alkyl or aryl lithium, or trimethyl (trifluoromethyl) silane (Ruppert's reagent).
  • Suitable examples of leaving groups for processes a) to c) are: fluoro, chloro, bromo, iodo, mesylate, tosylate or triflate.
  • Suitable examples of protecting groupsfor processes a) to c) are: tert-butyl oxycarbonyl (Boc), benzyl oxycarbonyl (Z), acetyl or trifluoracetyl.
  • Boc tert-butyl oxycarbonyl
  • Z benzyl oxycarbonyl
  • acetyl or trifluoracetyl tert-butyl oxycarbonyl
  • the reactions described above may be performed under standard conditions known to the person skilled in the art.
  • the intermediates described above are commercially available, are known in the art or may be prepared by known procedures and/or by the procedures shown above.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a /-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example hydroxylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a /-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a /-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • cortisone to the active steroid Cortisol by 1 l ⁇ HSDl oxo-reductase activity
  • a competitive immunoassay ⁇ 1 kit (Assay Designs, Inc: 800 Technology Drive, Ann Arbor, MI 48108, USA. Cortisol Enzyme Immunoassay kit: Cat No. 901-071).
  • DMSO dimethyl sulphoxide
  • the assay was carried out in a total volume of 200 ⁇ l consisting of cortisone (Sigma, Poole, Dorset, UK, l ⁇ M), glucose-6-phosphate (Roche Diagnostics, ImM), NADPH (Roche Diagnostics, lOO ⁇ M), glucose-6-phosphate dehydrogenase (Roche Diagnostics, 12.5 ⁇ g/ml), EDTA (Sigma, Poole, Dorset, UK, ImM), assay buffer (K 2 HPO 4 /KH 2 PO 4 , 10OmM) pH 7.5, recombinant 1 l ⁇ HSDl (5 ⁇ g/ml) plus test compound.
  • the assay plates were incubated for 30 minutes at 37°C after which time the reaction was stopped by the addition of 20 ⁇ l of ImM glycerrhetinic acid.
  • compositions of the invention which comprises a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • the compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal do
  • compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p_-hydroxybenzoate, and anti-oxidants, such as ascorbic acid.
  • Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example lieptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono
  • the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • metabolic syndrome relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of this syndrome.
  • Synonyms for "metabolic syndrome” used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term “metabolic syndrome” is used herein it also refers to Reaven's Syndrome, Insulin
  • a compound of formula (1), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament there is provided a compound of formula (1), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament.
  • production of or producing an 11 ⁇ HSDl inhibitory effect refers to the treatment of metabolic syndrome.
  • production of an 11 ⁇ HSDl inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity.
  • production of an 11 ⁇ HSDl inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.
  • an 11 ⁇ HSD 1 inhibitory effect refers to the treatment of cognitive disorders, such as improving the cognitive ability of an individual, for example by improvement of verbal fluency, verbal memory or logical memory, or for treatment of mild cognitive disorders. See for example WO03/086410 and references contained therein, and Proceedings of National Academy of Sciences (PNAS), 2001, 98(8), 4717-4721.
  • production of an 1 l ⁇ HSDl inhibitory effect is referred to this refers to the treatment of, delaying the onset of and/or reducing the risk of atherosclerosis - see for example J. Experimental Medicine, 2005, 202(4), 517-527.
  • ll ⁇ HSDl inhibitory effect refers to the treatment of Alzheimers and/or neurodegenerative disorders.
  • a method for producing an 11 ⁇ HSDl inhibitory effect in a wa ⁇ n-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1), or a pharmaceutically acceptable salt thereof.
  • a compound of formula (1) or a pharmaceutically acceptable salt thereof.
  • (1), or a pharmaceutically acceptable salt thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of ll ⁇ HSDl in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the inhibition of 1 l ⁇ HSDl described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets.
  • agents than might be co-administered with 11 ⁇ HSDl inhibitors, particularly those of the present invention may include the following main categories of treatment:
  • Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide), prandial glucose regulators (for example repaglinide, nateglinide), glucagon-like peptide 1 agonist (GLPl agonist) (for example exenatide, liraglutide) and dipeptidyl peptidase IV inhibitors (DPP-IV inhibitors);
  • sulphonylureas for example glibenclamide, glipizide
  • prandial glucose regulators for example repaglinide, nateglinide
  • GLPl agonist glucagon-like peptide 1 agonist
  • DPP-IV inhibitors dipeptidyl peptidase IV inhibitors
  • Insulin sensitising agents including PPAR ⁇ agonists (for example pioglitazone and rosiglitazone);
  • Agents that suppress hepatic glucose output for example metformin
  • Agents designed to reduce the absorption of glucose from the intestine for example acarbose
  • Agents designed to treat the complications of prolonged hyperglycaemia e.g. aldose reductase inhibitors
  • anti-diabetic agents including phosotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors
  • Anti-obesity agents for example sibutramine and orlistat
  • Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PP ARa agonists (f ⁇ brates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);
  • Antihypertensive agents such as, ⁇ blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), ⁇ antagonists and diuretic agents (eg. furosemide, benzthiazide); l l)Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors); antiplatelet agents (eg.
  • ⁇ blockers eg atenolol, inderal
  • ACE inhibitors eg lisinopril
  • calcium antagonists eg. nifedipine
  • angiotensin receptor antagonists eg candesartan
  • ⁇ antagonists and diuretic agents eg. furosemide, benzthiazide
  • Anti-inflammatory agents such as non-steroidal anti-infammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
  • LCMS were recorded on a system comprising Waters 2790 LC equipped with a Waters 996 Photodiode array detector and Micromass ZMD MS (using a Phenomenex® Synergi 4 ⁇ MAX-RP 8OA 50x2 mm column), or a Waters 2795 LC equipped with a Waters 2996 Photodiode array detector and Micromass ZQ MS (using a Phenomenex® Gemini 5 ⁇ C18 1 lOAngstrom 50x2 mm column), and eluting with a flow rate of 1.1 ml/min with 5% (Water/ Acetonitrile (1:1) + 1% formic acid) and a gradient increasing from 0-95% of acetonitrile over the first 4 minutes, the balance (95-0%) being water; mass spectra (MS) (loop) were recorded on a Micromass LCT equipped with HP 1100 detector, or a Thermo LCQ; unless otherwise stated the mass ion quoted is (M+H +
  • an Isolute SCX-2 column is referred to, this means an "ion exchange" extraction cartridge for adsorption of basic compounds, i.e. a polypropylene tube containing a benzenesulphonic acid based strong cation exchange sorbent, used according to the manufacturers instructions obtained from International Sorbent Technologies Limited, Dyffryn Business Park, Hengeod, Mid Glamorgan, UK, CF82 7RJ; viii) where an Isolute-NH2 column is referred to, this means an "ion exchange" extraction cartridge for adsorption of acidic compounds, i.e. a polypropylene tube containing a amino silane covalently bonded to a silica particle used according to the manufacturers instructions obtained from International Sorbent Technologies Limited, Dyffryn Business Park, Hengeod,
  • Isco CombiFlash Optix-10 parallel flash chromatography system is referred to this means an automated chromatography workstation capable of cany ing out up to 10 purifications in parallel via flash chromatography using pre packed silica cartridges; x) where a "Biotage 9Og silica column” is referred to this means an automated chromatography workstation capable of carrying out up to 4 purifications in parallel via flash chromatography using pre packed silica cartridges, eg Si 12+M available from Biotage Inc.
  • 1,4-Diazepane (5.49g, 54.8 mmol) and 3,4,5-trichloropyridine (2g, 3.0 mmol) were combined without solvent, and the mixture heated with stirring at 90 0 C for 2.5 hours.
  • the reaction mixture was cooled to room temperature and the product purified by flash column chromatography (CombiFlash ® Companion TM , 4Og silica column, eluting with a 10:1 mixture of DCM and methanol) to give the title compound as a yellow oil (2.06 g, 76% );
  • 1 H NMR 400 MHz, CDCl 3 ) ⁇ 1.88 - 1.94 (2H, m), 3.02 - 3.04 (2H, m), 3.09 (2H, t), 3.34 - 3.37 (4H, m), 8.39 (2H, s), m/z 246 (M+H) + [I].
  • Example 1 1 -(3,5-dichloropyridin-4-yl)-4-(4-fluorophenyl)sulfonyl- 1 ,4-diazepane
  • Example 2 1 -(2,4-dichlorophenyl)sulfonyl-4-(3 ,5-dichloropyridin-4-yl)- 1 ,4-diazepane
  • Example 3 1 -(3 ,5 -dichloropyridin-4-yl)-4-(3-methylphenyl)sulfony 1-1 ,4-diazepane
  • Example 4 l-(3,5-dichloropyridin-4-yl)-4-(4-methylphenyl)sulfonyl-l,4-diazepane
  • Example 5 l-(3,5-dichloropyridin-4-yl)-4-(2-methoxyphenyl)sulfonyl-l,
  • Example 16 1 -(3 , 5 -dichloropyridin-4-yl)-4- [3 -(trifiuoromethyl)phenyl] sulfonyl- 1 ,4- diazepane
  • Example 17 2-[[4-(3,5-dichloropyridin-4-yl)-l,4-diazepan-l-yl]sulfonyl]benzonitrile
  • Example 18 1 -(3 -chlorophenyl)sulfonyl-4-(3, 5 -dichloropyridin-4-yl)- 1,4-diazepane
  • Example 19 1 -(3 ,5-dichloropyridin-4-yl)-4-(2-methylphenyl)sulfonyl- 1 ,4-diazepane
  • 1,4-diazepane (1.3 g, 13 mmol) and 2-chloro-3-(trifluoromethyl) pyridine (473 mg, 2.6 mmol) were combined without solvent, and the mixture heated with stirring at 90 0 C for 3.5 hours.
  • the reaction mixture was cooled to room temperature, dissolved in EtOAc, and the solution washed sequentially with water (10 ml) and brine (10 ml).
  • Example 21 1 -(2-chlorophenyl)sulfonyl-4-(3 -chloropyridin-2-yl)- 1 ,4-diazepane
  • Example 25 1 -(2-chlorophenyl)sulfonyl-4-(2,6-dichlorophenyl)- 1 ,4-diazepane
  • Example 28 l-[4-[[4-[3-(trifluoromethyl)pyridin-2-yl]-l,4-diazepan-l- yl] sulfonyljphenyl] ethanone
  • Example 33 1,1,1 -trifluoro-2-[4-[[4-[3-(lrifluoromethyl)pyridin-2-yl]-l ,4-diazepan- 1 - yl]sulfonyl]phenyl]propan-2-ol

Abstract

La présente invention concerne des composés de formule (I) : dont les groupes variables sont définis ici. L'invention concerne également l'utilisation desdits composés dans l'inhibition de 11βHSD1, leurs procédés de fabrication et des compositions pharmaceutiques qui les comprennent.
PCT/GB2007/001507 2006-04-26 2007-04-25 Derives de diazepan-1-yl-sulfonyle pour le traitement du syndrome metabolique WO2007122411A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79526006P 2006-04-26 2006-04-26
US60/795,260 2006-04-26

Publications (1)

Publication Number Publication Date
WO2007122411A1 true WO2007122411A1 (fr) 2007-11-01

Family

ID=38227722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001507 WO2007122411A1 (fr) 2006-04-26 2007-04-25 Derives de diazepan-1-yl-sulfonyle pour le traitement du syndrome metabolique

Country Status (1)

Country Link
WO (1) WO2007122411A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2015073774A1 (fr) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Dérivés d'azépane et procédés de traitement d'infections par le virus de l'hépatite b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156433A2 (fr) * 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Pyridazineamines actives contre les virus
JP2001261657A (ja) * 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
WO2005115983A1 (fr) * 2004-04-07 2005-12-08 Kalypsys, Inc. Composes aryl sulfonamide et sulfonyl utilises comme modulateurs de ppar, et procedes de traitement de troubles metaboliques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156433A2 (fr) * 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Pyridazineamines actives contre les virus
JP2001261657A (ja) * 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
WO2005115983A1 (fr) * 2004-04-07 2005-12-08 Kalypsys, Inc. Composes aryl sulfonamide et sulfonyl utilises comme modulateurs de ppar, et procedes de traitement de troubles metaboliques

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BARF T ET AL: "Recent progress in 11-[beta]-hydroxysteroid dehydrogenase type 1 (11-[beta]-HSD1) inhibitor development", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 31, no. 3, March 2006 (2006-03-01), pages 231 - 243, XP002424785, ISSN: 0377-8282 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002, XP002442424, Database accession no. 439927-80-7 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, XP002442419, Database accession no. 478256-91-6 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, XP002442420, Database accession no. 478256-89-2 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, XP002442421, Database accession no. 478256-87-0 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, XP002442422, Database accession no. 478256-86-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, XP002442423, Database accession no. 478256-84-7 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002442415, Database accession no. 693776-93-1 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002442416, Database accession no. 693776-91-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002442417, Database accession no. 685115-86-0 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002442418, Database accession no. 651005-66-2 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2015073774A1 (fr) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Dérivés d'azépane et procédés de traitement d'infections par le virus de l'hépatite b
US9115113B2 (en) 2013-11-14 2015-08-25 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP2016537368A (ja) * 2013-11-14 2016-12-01 ノヴィラ・セラピューティクス・インコーポレイテッド アゼパン誘導体及びｂ型肝炎感染の治療方法
US9758489B2 (en) 2013-11-14 2017-09-12 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
AU2014348518B2 (en) * 2013-11-14 2019-01-03 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10364228B2 (en) 2013-11-14 2019-07-30 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN106255684B (zh) * 2013-11-14 2019-08-23 诺维拉治疗公司 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法

Similar Documents

Publication Publication Date Title
WO2007122411A1 (fr) Derives de diazepan-1-yl-sulfonyle pour le traitement du syndrome metabolique
WO2007135427A1 (fr) 1,4-disubstituées pipérazine et 1,4-disubstituées azépane inhibitrices de la 11 -béta-hydroxystéroid déshydrogénase 1
US20100022589A1 (en) Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
AU2009211215B2 (en) Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
US20070112000A1 (en) Chemical compounds
US5238942A (en) Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US20060058315A1 (en) 2-Oxo-ethanesulfonamide derivates
US8344016B2 (en) Pyrazole derivatives as 11-beta-HSD1 inhibitors
US20070219266A1 (en) N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders
EP1820504A1 (fr) Composé imine
AU2005315430A1 (en) Oxadiazole derivatives as DGAT inhibitors
JP2009539955A (ja) オキサゾール誘導体並びに糖尿病及び肥満症の治療におけるその使用
EP3813813A1 (fr) Composés
CA2072775A1 (fr) Triazolinones a substitution
AU2008326226B2 (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
CN101668524B (zh) 作为11-β-HSD1抑制剂的吡唑衍生物
BR112013013490B1 (pt) compostos e composição farmacêutica
WO2004076414A2 (fr) Nouveaux composes
JP3688714B2 (ja) アミノフェノール誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732545

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07732545

Country of ref document: EP

Kind code of ref document: A1